Other News Releases in Health Care & Hospitals
DataCare Names Mat Malone Director of Engineering
Finding a Cure: Providing Adequate Healthcare to Immigrants in Detention
Dr. Paul Pui-Hay But, Ph.D. Joins Bionovo, Inc. Scientific Advisory Board
Other News Releases in New Products & Services
Rajiv Dulepet, Developer of Mass Opinion Business Intelligence, Creates New Computational Framework for Caltech
Syncfusion Releases Essential Studio 2010 Volume 1 Featuring Support for Visual Studio 2010 and Microsoft .NET 4.0
Leading Toy Manufacturer Hasbro Expresses Interest in Majic Wheels Toy Car
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries, Hispanic-oriented News
Ultrasound Treats Localized Prostate Cancer
High Intensity Focused Ultrasound (HIFU) now Available at New Location in
Mexico
CANCUN, Mexico, Nov. 30 /PRNewswire/ -- A new clinic in Cancun, Mexico
will offer treatment of localized prostate cancer with HIFU, an ultrasound
therapy. This is the second facility in Mexico to offer this therapy; HIFU
is also available at Hospital San Javier located in Puerto Vallarta.
This month, HIFU became available at Galenia Hospital, a private,
functional hospital with a modern, minimalist atmosphere especially
designed for the comfort of both patients and physicians. Galenia opened in
Cancun in March 2006 to offer services to patients at the popular travel
destination. Adding the Cancun facility to the locations that already offer
HIFU in Mexico, Canada, the Dominican Republic and the Bahamas allows for
optimal flexibility for those seeking HIFU.
Cancun becomes the seventh location outside of the U.S. in North and
South America to offer HIFU for localized prostate cancer and BPH. Other
locations include Toronto, Canada; Niagara Falls, Canada; Puerto Vallarta,
Mexico; Buenos Aires, Argentina; Santo Domingo, Dominican Republic and San
Jose, Costa Rica.
The Sonablate(R) 500, the HIFU treatment device, is not approved for
use in the U.S. The device remains investigational in the U.S. and is being
studied for the treatment of prostate cancer in clinical trials in the U.S.
The U.S. Food and Drug Administration has made no decision as to the safety
or efficacy of the Sonablate(R) 500 for the treatment of prostate cancer.
The Sonablate(R) 500 is intended for use by licensed practitioners. You
should consult your doctor for further information about HIFU with the
Sonablate(R) 500. For more information about HIFU in Cancun or any other
International HIFU Centers in Canada, the Caribbean, and Latin America,
visit http://www.InternationalHIFU.com.
The Sonablate(R) 500 is developed and owned by Focus Surgery, Inc. and
manufactured under contract by Misonix, Inc. ( MSON) which also
holds distribution rights in Europe. Takai Hospital Supply Ltd. and THS
International distribute the Sonablate(R) 500 in Southeast Asia and the
Middle East.
SOURCE Therapeutic Ultrasound Management













